Skip to main content

Table 1 Description of 420 TCGA ccRCC patients

From: 8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness

  N (%)
Sex  
 Female 137 (32.6%)
 Male 283 (67.4%)
Max tumor size  
 N 376
 Mean (SD) 6.5 (3.5)
 Median 5.5
 Q1, Q3 4.0, 8.5
 Range (1.1–25.0)
Stage  
 Missing 44
 Stage I 176 (46.8%)
 Stage II 135 (35.9%)
 Stage IV 65 (17.3%)
Grade  
 Missing 44
 G1 7 (1.9%)
 G2 156 (41.5%)
 G3 152 (40.4%)
 G4 60 (16.0%)
 GX 1 (0.3%)
Percent necrosis  
 Missing 64
 0 189 (53.1%)
 2 4 (1.1%)
 3 2 (0.6%)
 5 42 (11.8%)
 8 1 (0.3%)
 10 23 (6.5%)
 15 13 (3.7%)
 20 6 (1.7%)
 25 4 (1.1%)
 30 72 (20.2%)
SSIGN group  
 Missing 65
 Low risk (0–3) 159 (44.8%)
 Intermediate risk (4–7) 115 (32.4%)
High risk (8+) 81 (22.8%)
BAP1 mutated  
 Missing 44
 No 342 (91.0%)
 Yes 34 (9.0%)
PBRM1 mutated  
 Missing 44
 No 257 (68.4%)
 Yes 119 (31.6%)
SETD2 mutated  
 Missing 44
 No 328 (87.2%)
 Yes 48 (12.8%)
VHL mutated  
 Missing 44
 No 226 (60.1%)
 Yes 150 (39.9%)
ccA/ccB expression subtype  
 Missing 68
 ccB 168 (47.7%)
 ccA 184 (52.3%)